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Achieving high coverage in Rwanda’s national human papillomavirus 
vaccination programme 
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Background
Human papillomavirus (HPV) is a sexually transmitted virus 
found in virtually all cases of cervical cancer,1 which kills 
275 000 women every year2 and is the biggest contributor to 
years of life lost from cancer among women in the developing 
world.3 Two HPV vaccines developed in recent years – Merck’s 
quadrivalent Gardasil and GlaxoSmithKline’s bivalent Cer-
varix – have been prequalified by the World Health Organiza-
tion (WHO) and approved by national governments in many 
countries, including Rwanda. These vaccines represent a mile-
stone in biomedical progress towards mitigating the burden of 
cervical cancer.4 Vaccination programmes have changed the 
landscape of global health drastically by enabling countries to 
re-evaluate funding priorities and to invest in prevention when 
cost-effective.5 However, 15 to 20 years usually pass between 
the introduction of a vaccine in rich and poor countries.6
In recent decades, routine screening programmes have 
reduced cervical cancer morbidity and mortality in high-
income countries, and this trend is expected to accelerate as 
vaccination coverage is scaled up.7 As a result, 77% of new 
cases8 and 88% of deaths from the disease now occur in de-
veloping countries.2 A five-year delay in introducing the HPV 
vaccine to these countries would result in 1.5 to 2 million 
preventable deaths.2
Cervical cancer is the most common cancer among 
women in Rwanda,9 a country in eastern African with more 
than 11 million inhabitants. In 2010, 986 cases of cervical 
cancer were diagnosed in Rwanda and 678 women died from 
the disease.9 That same year, Rwanda evaluated options for 
HPV vaccination rollout and decided to pursue a partnership 
with Merck to offer Rwanda’s young girls the opportunity to 
receive a life-saving vaccine.
A growing body of scientific literature has emerged in 
recent years concerning the use of the HPV vaccine in the 
developing world,2,10 but very little evidence on the success 
and replicability of nationwide delivery programmes, like 
Rwanda’s, has been published. In this article, we describe the 
process by which Rwanda became the world’s first low-income 
country to provide universal access to the HPV vaccine.
Context
Before 2011, neither cervical cancer screening nor HPV vac-
cination was available in public health facilities in Rwanda; 
only a few private clinics and nongovernmental organizations 
offered screening services. Aware that cervical cancer is highly 
prevalent in Rwanda, the Ministry of Health considered the 
overwhelmingly positive evidence of the effectiveness of the 
HPV vaccine to be a call to action.
In April 2009, Rwanda’s First Lady met with senior Merck 
officials to initiate advocacy for the HPV vaccine on behalf of 
women in Rwanda. An internal technical discussion then oc-
curred between Merck and the Ministry of Health, followed by 
conversations with development partners in Rwanda’s health 
sector. In April and October 2010, Merck representatives 
visited Rwanda to work under the leadership of the Ministry 
of Health in developing a national cervical cancer prevention 
strategy. Rwanda’s National Strategic Plan for the Prevention, 
Control, and Management of Cervical Lesions and Cancer11 
Problem Virtually all women who have cervical cancer are infected with the human papillomavirus (HPV). Of the 275 000 women who die 
from cervical cancer every year, 88% live in developing countries. Two vaccines against the HPV have been approved. However, vaccine 
implementation in low-income countries tends to lag behind implementation in high-income countries by 15 to 20 years.
Approach In 2011, Rwanda’s Ministry of Health partnered with Merck to offer the Gardasil HPV vaccine to all girls of appropriate age. The 
Ministry formed a “public–private community partnership” to ensure effective and equitable delivery.
Local setting Thanks to a strong national focus on health systems strengthening, more than 90% of all Rwandan infants aged 12–23 months 
receive all basic immunizations recommended by the World Health Organization. 
Relevant changes In 2011, Rwanda’s HPV vaccination programme achieved 93.23% coverage after the first three-dose course of vaccination 
among girls in grade six. This was made possible through school-based vaccination and community involvement in identifying girls absent 
from or not enrolled in school. A nationwide sensitization campaign preceded delivery of the first dose.
Lessons learnt Through a series of innovative partnerships, Rwanda reduced the historical two-decade gap in vaccine introduction between 
high- and low-income countries to just five years. High coverage rates were achieved due to a delivery strategy that built on Rwanda’s 
strong vaccination system and human resources framework. Following the GAVI Alliance’s decision to begin financing HPV vaccination, 
Rwanda’s example should motivate other countries to explore universal HPV vaccine coverage, although implementation must be tailored 
to the local context.
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includes screening and vaccination 
programmes for women between 35 and 
45 years of age, the specifics of which 
will be detailed in future articles. A 
memorandum of understanding signed 
in December 2010 guaranteed Rwanda 
three years of vaccinations at no cost 
and concessional prices for future doses.
On 26 and 27 April 2011, 93 888 
Rwandan girls in primary grade six re-
ceived their first shot of Gardasil with no 
out-of-pocket payment. Data collected 
by the Ministry of Health during the 
first round of vaccination showed that 
94 141 girls were present at school and 
that 4 651 girls were either absent or not 
enrolled, resulting in a total of 98 792 
eligible girls across Rwanda. The pro-
gramme’s first round achieved 95.04% 
coverage, the second 93.90% and the 
third, 93.23% (Table 1).
Rwanda’s health sector
Driven by the pursuit of equity, value 
and quality, the health sector in Rwanda 
has made immense progress in recent 
years. Through a decentralization strategy 
harnessing Rwanda’s 45 000 community 
health workers, the Ministry of Health and 
its partners have succeeded in decreasing 
the burden of major infectious diseases 
and have scaled up disease prevention 
programmes efficiently and effectively. 
Between 2005 and 2010, Rwanda reduced 
malaria incidence by 70% and under-five 
mortality by 50%. The country increased 
the proportion of infants aged 12–23 
months receiving all basic WHO immuni-
zations from 75.2% to 90.1% (with all but 
oral polio vaccine coverage rates exceed-
ing 95% in 2010) and assured universal ac-
cess to antiretroviral therapy.12,13 Rwanda 
has also strategically positioned itself to 
tackle non-communicable diseases by 
building on its successful integration 




Three early decisions were crucial to 
the success of Rwanda’s HPV vaccine 
rollout. First, the Ministry of Health 
decided in September 2010 to widen its 
technical working group on vaccinations 
to include the Ministry of Education, 
the Ministry of Gender and Family 
Promotion, the Center for Treatment 
and Research on AIDS, Tuberculosis, 
Malaria, and other Epidemics, and 
health workers engaged in cancer care. 
Multidisciplinary subcommittees were 
tasked with identifying cold chain re-
quirements; numbers of girls in and out 
of school; nurse and community health 
worker training capacity; procurement 
and distribution logistics; a budget for 
implementation; education and sen-
sitization requirements; and tools for 
data collection and social mobilization. 
Committees met as often as needed – 
often every other day – for about four 
months. After the memorandum of 
understanding between Merck and the 
government of Rwanda was signed, the 
following two months were spent devis-
ing a strategic plan for rollout prepara-
tion, implementation and evaluation.
Concurrently, a nationwide popula-
tion sensitization campaign was planned 
and undertaken months in advance of 
vaccination. Speeches by health-care 
professionals, local government officials, 
clergy and the First Lady were made to 
inform parents and children of the new 
vaccine. Announcements via newspa-
pers, magazines, radio and television 
were included in the communications 
strategy. Teachers were trained and en-
couraged to discuss cervical cancer and 
the HPV vaccine with students.
With technical assistance from the 
US Centers for Disease Control and 
Prevention (CDC) and the International 
Center for AIDS Care and Treatment 
Programs (ICAP) at Columbia Uni-
versity, Rwanda’s Ministry of Health 
conducted a situational analysis in 
March 2011 using in-depth interviews 
and focus group discussions to assess 
the knowledge, attitudes and beliefs 
of key stakeholders pertaining to HPV 
vaccination. The systematic inclusion of 
local leaders, community health work-
ers and teachers in the vaccine delivery 
strategy combined with Merck’s in-kind 
support to constitute a “public-private-
community partnership” for effective 
programme implementation specific to 
the Rwandan context.
The second major decision was to 
partner with the Ministry of Education 
to design a school-based strategy to 
deliver the standard three doses of the 
HPV vaccine. Because 98% of Rwandan 
girls attend primary school,16 imple-
menters felt that the highest coverage 
rates could be attained through schools. 
Some girls in rural settings are unaware 
of their exact ages, and a demonstration 
project in Uganda described difficulties 
identifying girls through an age-based 
programme,10 so Rwanda elected to 
pursue a grade-based strategy.
Third, the technical working group 
decided on a multi-phased vaccina-
tion strategy spanning three years 
(Fig. 1). Every year beginning in 2011, 
girls enrolled in primary grade six will 
receive the full three-dose course of 
HPV vaccine. During the programme’s 
second and third years, a “catch-up” 
phase targeting girls in the third year of 
secondary school will ensure complete 
coverage of all pre-adolescent and ado-
lescent girls. In 2014 and beyond, only 
primary grade six vaccinations will be 
necessary.
Each course of vaccination takes 
place over six days: school-based vac-
cinations across the country during 
the first two days, out-of-school girls 
are tracked and vaccinated on the third 
day, and surveillance of adverse events 
is conducted over the remaining three 
days. The vaccination is a voluntary 
opt-out intervention offered to all girls 
in the targeted age groups, regardless of 
their school enrolment status. Parents 
and guardians had been instructed 
through the massive communications 
and media campaigns to accompany 
their daughters to school on the day 
when the first dose was going to be ad-
ministered. If a parent or guardian did 
not come to the school, the girl did not 
receive the vaccine. On the days when 
vaccines are administered, which the 
schools now designate as educational 
“health days”, local health-care providers 
and teachers discuss topics pertaining to 
Table 1. Cumulative human papillomavirus vaccination coverage, by vaccination round, 
Rwanda, 2011
Coverage Round 1 Round 2 Round 3
Girls vaccinated in school, no. 91 752 89 704 88 927
Girls vaccinated outside school, no. 2 136 3 066 3 180
Total no. of girls vaccinated 93 888 92 770 92 107
Cumulative coverage (%) 95.04 93.90 93.23
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hygiene, nutrition, infectious diseases 
and reproductive health.
The vaccination programme techni-
cal working group chose to target girls 
in primary grade six because most of 
them are not yet sexually active but have 
reached an appropriate age for initiat-
ing sexual education. In Rwanda, the 
median age of sexual debut is 20.7 years 
and only 2.7% of girls have had sex by 
age 15.13
Delivery challenges
During the first phase of the vaccination 
rollout, one of the greatest challenges 
faced by implementers was making the 
population across the country aware of 
eligibility guidelines for the HPV vac-
cination. Some parents wanted to have 
all of their children immunized, and 
several female teachers in schools where 
the vaccine was delivered also asked to 
be vaccinated. Through radio and on-
site communication, representatives of 
the Ministry of Health acknowledged 
the potential benefit of vaccinating all 
women at risk for cervical cancer but 
explained that this national programme 
was intended only for girls before sexual 
debut. They also explained that there 
would be a “catch-up” phase of HPV vac-
cination targeting third-year secondary 
school students.
Targeted action was taken for the 
girls who were sick or otherwise absent 
from school on vaccination days, in ad-
dition to the small number of girls who 
should be in primary grade six but were 
not enrolled in school at the time of the 
vaccination rollout. To make sure that 
no eligible girls missed the opportunity 
to benefit from the vaccine, Rwanda’s 
45 000 community health workers were 
mobilized for active tracing of girls who 
were enrolled in primary grade six but 
absent on a vaccination day, as well as 
the small number of girls who were 12 
years old but not enrolled in school. 
After being identified by community 
health workers, girls from both groups 
were vaccinated at the local health centre 
(Table 2).
Resistance
The HPV vaccine rollout in Rwanda, like 
other progressive public health policies 
in Africa, has met with some resistance 
from the international community.17 
Concerns over the initially high fixed 
costs of vaccination have led some to 
suggest that a focus on cervical cancer 
prevention might detract scarce re-
sources from other more “cost-effective” 
child health interventions. Indeed, state-
of-the-art health technologies are gener-
ally expensive and health ministries face 
difficult choices when making budget 
allocations. However, Rwanda acted on 
its decision to tackle non-communicable 
diseases in a systematic way by accepting 
Merck’s offer to provide free vaccines 
for the first three years of the HPV 
vaccination programme. High-level 
leaders are committed to ensuring the 
long-term integration of a rights-based 
cervical cancer prevention, care and 
treatment programme into the basic 
package of health services. As more 
low- and middle-income countries fol-
low Rwanda’s example and confront the 
untallied cost of inaction with respect to 
cervical cancer, vaccine market dynam-
ics and tiered pricing agreements will 
most likely drive down vaccine prices in 
these settings, as has occurred with the 
pneumococcal conjugate vaccine (which 
Rwanda was also the first low-income 
country to roll out).18
Implications
A successful nationwide HPV vac-
cination programme requires a well-
established vaccine delivery system with 
adequate cold chain, transportation, hu-
man resources and monitoring capacity. 
Collaboration between public and pri-
vate institutions within the framework 
of strong national ownership appears to 
be a prerequisite for long-term sustain-
ability. To assure high vaccine uptake, 
the health system should have a strong 
outreach communication capacity to 
clearly address questions on the part of 
girls, parents and health workers about 
vaccine safety and efficacy and the ex-
clusive focus on young adolescent girls.
Favourable outcomes from HPV 
vaccine rollouts and similar initiatives 
do not occur by chance; they result 
from strong coordination, national 
ownership, strategic planning, com-
prehensive monitoring (especially the 
reporting of side-effects and adverse 
reactions through teacher training) 
and good managerial capacity. Senior 
Ministry of Health officials in Rwanda 
acknowledged that an emphasis on 
health systems strengthening by the 
government, The GAVI Alliance, the 
President’s Emergency Plan for AIDS 
Relief and The Global Fund to Fight 
AIDS, Tuberculosis and Malaria was key 
to the success of HPV vaccine rollout in 
the country.
We are encouraged by the promis-
ing initial results of the HPV vaccina-
tion programme in Rwanda, which 
has attained 93.23% coverage after the 
first three-dose course of vaccination. 
Rwanda’s example should motivate other 
countries to expand their vaccination 
programmes to include the HPV vac-
cine, with due customization according 
to their epidemiological, economic, 
political, and health system contexts, es-
pecially now that the GAVI Alliance has 
included the vaccine in its immunization 
package and that Merck has lowered the 
price to 5 United States dollars per dose 
for GAVI Alliance eligible countries.19 ■
Competing interests: None declared.
Fig. 1. Human papillomavirus vaccination rollout phases, Rwanda, 2011–2014
School year 2011 2012 2013 2014
Primary grade 6
Secondary  grade 3
Table 2. Human papillomavirus vaccination coverage of girls not enrolled in or absent 
from school, by vaccination round, Rwanda, 2011
Coverage Round 1 Round 2 Round 3
Girls vaccinated outside school, no. 2136 3066 3180
Total girls outside school, no. 4651 3679 3734
Coverage of girls outside school (%) 45.93 83.34 85.16
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صخلم
ادناور في يشربلا يميللحا مرولا سويرف دض ينطولا عينمتلا جمانرب في ةيلاع ةيطغت قيقتح
 ًابيرقت  محرلا  قنع  ناطسرب  تاباصلما  تاديسلا  عيجم  ةلكشلما
 .)HPV(  يشربلا  يميللحا  مرولا  سويرف  ىودعب  تاباصم
 نم ةافولل ضرعتت ةأرما 275000 لياجمإ نم % 88 ةبسن شيعتو
 ةقفاولما  تتمو .ةيمانلا  نادلبلا  في اًيونس محرلا قنع ناطسر ءارج
 ،كلذ عمو .يشربلا  يميللحا مرولا  سويرف ةحفاكلم ينحاقل  لىع
 ذيفنتلا نع رخأتلا لىإ لخدلا ةضفخنم نادلبلا في حاقللا ذيفنت ليمي
 .ةنس 20 لىإ 15 وحنب لخدلا ةعفترم نادلبلا في
 ةكاشر ةيدناورلا  ةحصلا ةرازو تدقع ،2011  ماع في بولسلأا
Gardasil يشربلا يميللحا مرولا سويرف حاقل يرفوتل كيرم عم
 ينب ةكاشر”  ةرازولا تلكشو .ةبسانلما رماعلأا نم تايتفلا عيملج
 لاعف  لكشب  حاقللا  ءاتيإ  نماضل  “صالخاو  ماعلا  ليحلما  عمتجلما
 .لداعو
 مظنلا  زيزعت  لىع  يوقلا  ينطولا  زيكترلا  لضفب  ةيلحلما  عقاولما
 ينيدناورلا  عضرلا  عيجم  نم  %  90  نع  ديزي  ام  لصيح  ،ةيحصلا
 تامدخ  عيجم  لىع  ارهش  23  12  و  ينب  مهرماعأ  حواترت  نيذلا
.ةيلماعلا ةحصلا ةمظنم ابه صيوت يتلا عينمتلا
 دض  عينمتلا  جمانرب  ققح  ،2011  ماع  في  ةلصلا  تاذ  تا ّريرغتلا
 % 93.23  ةبسنب ةيطغت ادناور في يشربلا يميللحا مرولا سويرف
 فصلا في تايتفلا  ينب ثلاثلا حاقللا  تاعرج نم ةعفد لوأ دعب
 عمتجلما كاشرإو سيردلما عينمتلا للاخ نم اذه ققتحو .سداسلا
 تلاجسلما يرغ وأ ةسردلما  نع تابيغتلما  تايتفلا  ديدتح في ليحلما
.ينطولا ديعصلا لىع ةيعوت ةلحم لىولأا ةعرلجا ءاتيإ قبسو .ابه
 تاكاشرلا نم ةلسلس للاخ نم ادناور تضفخ ةدافتسلما سوردلا
 ينب  حاقللا  لماعتسا  في  ءدبلاب  ةييخراتلا  نيدقعلا  ةرغث  ةيراكتبلاا
 ىزعتو .طقف تاونس سخم لىإ لخدلا ةضفخنمو ةعفترم نادلبلا
 ءاتيلإا  ةيجيتاترسإ  لىإ  اهقيقتح  مت  يتلا  ةيلاعلا  ةيطغتلا  تلادعم
 ينيوقلا ةيشربلا دراولما راطإو عينمتلا ماظن ساسأ لىع تماق يتلا
 تاحاقللا  لجأ نم يلماعلا  فلاحتلا  رارق  باقعأ  فيو .ادناور في
 ،يشربلا يميللحا مرولا سويرف دض عينمتلا ليوتم ءدبب عينمتلاو
 ةيطغتلا  ثحب  لىإ  ىرخلأا  نادلبلا  ادناور  جذومن  عفدي  نأ  يغبني
 نم  مغرلا  لىع  يشربلا  يميللحا  مرولا  سويرف  حاقلل  ةلماشلا



























Atteinte d’un niveau de couverture élevé pour le programme national rwandais de vaccination contre le papillomavirus humain 
Problème Pratiquement toutes les femmes touchées par le cancer 
du col de l’utérus sont infectées par le virus du papillome humain 
(VPH). Parmi les 275 000 femmes qui meurent chaque année d’un 
cancer du col utérin, 88% d’entre elles vivent dans des pays en voie 
de développement. Deux vaccins contre le VPH ont été approuvés. 
Toutefois, l’instauration du vaccin dans les pays à revenu faible reste 
à la traîne depuis 15 à 20 ans par rapport à sa mise en œuvre dans 
les pays à revenu élevé.
Approche En 2011, le ministère de la Santé du Rwanda a créé un 
partenariat avec Merck pour offrir le vaccin Gardasil contre le VPH à 
toutes les filles d’âge approprié. Le ministère a établi un «partenariat 
communautaire public-privé» pour en assurer une délivrance efficace 
et équitable.
Environnement local Grâce à un effort national majeur en matière de 
renforcement des systèmes de santé, plus de 90% de tous les nourrissons 
rwandais âgé de 12 à 23 mois reçoivent l’ensemble des vaccins de base 
recommandés par l’Organisation mondiale de la Santé.
Changements significatifs En 2011, le programme rwandais de 
vaccination contre le VPH a atteint une couverture de 93,23% après la 
première cycle de trois doses de vaccin parmi les filles de niveau CM2. 
Cela a été rendu possible grâce à une vaccination en milieu scolaire et 
à l’implication communautaire dans l’identification des filles absentes 
ou non inscrites à l’école. Une campagne nationale de sensibilisation a 
précédé l’administration de la première dose.
Leçons tirées Grâce à une série de partenariats novateurs, le Rwanda a 
réduit l’écart historique de deux décennies à seulement cinq ans quant 
à l’introduction d’un vaccin dans les pays à revenu élevé et faible. Des 
taux de couverture élevés ont été atteints grâce à une stratégie de 
délivrance basée sur un système de vaccination solide au Rwanda et à 
une organisation efficace des ressources humaines. Suite à la décision 
de l’Alliance GAVI d’initier le financement de la vaccination contre le 
VPH, l’exemple du Rwanda devrait inciter d’autres pays à envisager une 
couverture totale du vaccin contre le VPH, bien que la mise en œuvre 
doive être adaptée au contexte local.
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Резюме 
Широкий охват национальной программой вакцинации против вируса папилломы человека в Руанде
Проблема Практически все женщины, у которых диагностирован 
рак шейки матки, инфицированы вирусом папилломы человека 
(ВПЧ).Из275 000женщин, которые ежегодно умирают от рака 
шейки матки,88%живут в развивающихся странах. Были одобрены 
две вакцины против ВПЧ.Тем не менее, страны с низким уровнем 
дохода имеет тенденцию отставать в вопросах вакцинации от 
стран с высоким доходом на 15-20 лет.
Подход В 2011 году Министерство здравоохранения Руанды в 
сотрудничестве с компанией Merck начало программу вакцинации 
для всех девочек соответствующего возраста вакциной Гардасил 
(Gardasil) против ВПЧ. Министерство создало«государственно-
частное партнерство», чтобы обеспечить эффективную и равную 
вакцинацию.
Местные условия Благодаря пристальному вниманию государства 
к укреплению систем здравоохранения более 90% детей в Руанде 
получают все основные прививки, рекомендованные Всемирной 
организацией здравоохранения.
Осуществленные перемены В 2011 г.программа вакцинации 
против ВПЧ в Руанде охватила первой из трех доз вакцины 
93,23% девочек, учащихся в шестых классах. Это стало возможным 
благодаря школьной вакцинации и участию общественности 
в нахождении девочек, которые отсутствовали или вообще 
не ходили в школу. Введению первой дозы предшествовала 
общенациональная кампания сенсибилизации.
Выводы С помощью ряда инновационных партнерств Руанде 
удалось за пять лет сократить исторический разрыв в вопросах 
вакцинации размером в два десятилетия, существующий 
между странами с высоким и низким уровнем дохода. 
Высокие показатели охвата были достигнуты за счет стратегии, 
построенной на сильной системе вакцинации в Руанде и 
высоком человеческом потенциале. Вслед за решением Альянса 
GAVI начать финансирование вакцинации против ВПЧ, пример 
Руанды должен мотивировать другие страны рассмотреть 
вопрос универсального охвата вакциной против ВПЧ, однако 
реализация данных мероприятий должна быть адаптирована к 
местным условиям.
Resumen
Cómo alcanzar una cobertura elevada en el programa nacional de vacunación contra el virus del papiloma humano en Rwanda 
Situación Casi todas las mujeres que tienen cáncer cervicouterino 
están infectadas con el virus del papiloma humano (VPH). De 
las 275 000 mujeres que fallecen anualmente debido al cáncer 
cervicouterino, el 88% vive en países en desarrollo. Se han aprobado 
dos vacunas contra el VPH, no obstante, la implantación de la vacuna en 
países de ingresos bajos tiende a quedar entre 15 y 20 años por detrás 
de su aplicación en países de ingresos altos.
Enfoque En 2011, el Ministerio de Sanidad de Rwanda se asoció con 
Merck para ofrecer la vacuna Gardasil contra el VPH a todas las niñas en la 
edad adecuada. El Ministerio formó una «asociación comunitaria público-
privada» para garantizar un reparto eficaz y equitativo de la misma.
Marco regional Más del 90% de los niños de 12 a 23 meses de edad 
en Rwanda ha recibido todas las vacunas básicas recomendadas 
por la Organización Mundial de la Salud gracias a los esfuerzos 
gubernamentales por mejorar los sistemas sanitarios. 
Cambios importantes El programa de vacunación contra el VPH en 
Rwanda alcanzó una cobertura del 93,23% entre las niñas de sexto curso 
en el año 2011 al cabo de la primera ronda de vacunación con las tres 
dosis. Esto fue posible a través de la vacunación escolar y gracias a la 
participación de la comunidad para identificar a las niñas que faltaban o 
no estaban matriculadas en el colegio. Una campaña de sensibilización 
a escala nacional precedió la entrega de la primera dosis.
Lecciones aprendidas A través de una serie de asociaciones 
innovadoras, Rwanda redujo a tan solo cinco años la brecha histórica 
de dos décadas en cuanto a la introducción de la vacuna entre países 
de ingresos altos y bajos. Una estrategia de reparto construida sobre 
el sólido sistema de vacunación y el marco de recursos humanos de 
Rwanda permitió alcanzar una cobertura elevada. Siguiendo la decisión 
de la GAVI Alliance de comenzar a financiar la vacuna contra el VPH, 
el ejemplo de Rwanda debería animar a otros países a investigar la 
cobertura de la vacuna universal contra el VPH, aunque su aplicación 
deberá adaptarse al contexto local.
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